Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- The Kirklin Clinic at Acton Road — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
+ 473 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Locations: - Alabama Oncology, Shelby — Alabaster, Alabama
- Alabama Oncology, Bessemer — Bessemer, Alabama
- Alabama Oncology, St Vincent's Birmingham — Birmingham, Alabama
+ 238 more sites in the U.S.
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Locations: - Pioneer Research Center — Bullhead City, Arizona
- Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
+ 219 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Locations: - Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center — Fullerton, California
- Providence St. Jude Medical Center — Fullerton, California
+ 81 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Locations: - Research Site — Tucson, Arizona
- Research Site — Springdale, Arkansas
- Research Site — Anaheim, California
+ 74 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Locations: - Tower Cancer Research Foundation — Beverly Hills, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Cedars-Sinai Cancer - Tarzana — Tarzana, California
+ 69 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
+ 68 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Locations: - Research Site — Anchorage, Alaska
- Research Site — Tucson, Arizona
- Research Site — Little Rock, Arkansas
+ 60 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Locations: - Alaska Oncology and Hematology — Anchorage, Alaska
- City of Hope - Phoenix — Goodyear, Arizona
- Community Cancer Institute (CCI) — Clovis, California
+ 58 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …
Sponsor: Pfizer
NCT ID: NCT07226999
Locations: - Highlands Oncology Group — Fayetteville, Arkansas
- Highlands Oncology Group — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
+ 51 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Locations: - Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology — Birmingham, Alabama
- Alaska Oncology and Hematology, LLC — Anchorage, Alaska
- John Muir Clinical Research Center — Concord, California
+ 50 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Locations: - Banner MD Anderson Cancer Center ( Site 0181) — Gilbert, Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0163) — Tucson, Arizona
- Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
+ 49 more sites in the U.S.